Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. As of September 30, 2024, the Company owned and operated a portfolio of 2,271 properties, located in 49 states and containing approximately 47.2 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC".

Agree Realty Corporation

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM...

Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

Insiders have been trading these 5 stocks: (($BZUN)), (($PONY)), (($ADC)), (($SPRU)) and (($WVE)). Here is a breakdown of their recent trades and t...

Baozun, Pony AI, Agree Realty, Spruce, Wave Shock

ADC Therapeutics Ltd (($ADCT)) has held its Q4 earnings call. Read on for the main highlights of the call. ADC Therapeutics’ latest earnings call s...

ADC Therapeutics Earnings Call: Trials, Cash And Risks

Agree Realty ( ($ADC) ) has provided an announcement. On April 2, 2026, Agree Realty Corporation reported the weighted-average number of its common...

Agree Realty Updates Share Count and Dilution Metrics

An announcement from ACDC Metals Ltd ( ($AU:ADC) ) is now available. ACDC Metals has advised that, effective 24 March 2026, it has relocated its re...

ACDC Metals Relocates Registered Office to Melbourne CBD

Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on Douglas Emmett (DEI – Research Report) and Agree ...

Analysts Offer Insights on Real Estate Companies: Douglas Emmett (DEI) and Agree Realty (ADC)

Barclays analyst Richard Hightower maintained a Hold rating on Agree Realty today and set a price target of $81.00. According to TipRanks, Hightowe...

Agree Realty (ADC) Receives a Hold from Barclays

In a report released on March 10, Leonid Timashev from RBC Capital maintained a Buy rating on ADC Therapeutics, with a price target of $6.00. The c...

Current Quarter	$1.09	Next Quarter	$1.1
Current Year	$4.43	Next Year	$4.65
QoQ Growth	+0.9%	YoY Growth	+5.0%
3Y EPS CAGR	+0.0%	Target Price	$84.32
Consensus	Buy	Upside	+8.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADC	$77.97	0.00%	833.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ADC	$77.97	0%	833.40K
3
4
5
6

ADC

ADC

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Agree Realty Corporation Data in Excel

Get Agree Realty Corporation Data in Excel